sur ABIVAX (EPA:ABVX)
Abivax Reveals Strategic Plans for 2026
Abivax has announced its 2026 corporate outlook, focusing on market insights and clinical advancements. With the ulcerative colitis (UC) market predicted to expand significantly, obefazimod is positioned as a potential market leader in this space. This follows positive feedback from the ABTECT Phase 3 safety monitoring report, indicating no new safety concerns.
Abivax anticipates topline results from the ABTECT-UC Phase 3 trial by late Q2 2026, with a regulatory filing in the US planned for late 2026. Concurrently, the ENHANCE-CD Phase 2b trial for Crohn’s disease is underway, with results expected towards the end of 2026. The company’s cash runway extends into Q4 2027.
Additionally, 22 abstracts related to obefazimod will be presented at the European Crohn’s and Colitis Organization conference in February 2026. These developments underline Abivax’s commitment to advancing therapeutic options in chronic inflammatory diseases.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX